Erratum: Dual inhibition of canonical and noncanonical NF-kB pathways demonstrates significant antitumor activities in multiple myeloma (Clin Cancer Res (2019) 18(4669–81)Doi:10.1158/1078-0432.CCR-12-0779)

Claire Fabre; Naoya Mimura; Kathryn Bobb; Sun Young Kong; Gull u. Gorgun; Diana Cirstea; Yiguo Hu; Jiro Minami; Hiroto Ohguchi; Jie Zhang; Jeffrey Meshulam; Ruben D. Carrasco; Yu Tzu Tai; Paul G. Richardson; Teru Hideshima; Kenneth C. Anderson

doi:10.1158/1078-0432.CCR-19-0959

Erratum: Dual inhibition of canonical and noncanonical NF-kB pathways demonstrates significant antitumor activities in multiple myeloma (Clin Cancer Res (2019) 18(4669–81)Doi:10.1158/1078-0432.CCR-12-0779)

Claire Fabre, Naoya Mimura, Kathryn Bobb, Sun Young Kong, Gull u. Gorgun, Diana Cirstea, Yiguo Hu, Jiro Minami, Hiroto Ohguchi, Jie Zhang, Jeffrey Meshulam, Ruben D. Carrasco, Yu Tzu Tai, Paul G. Richardson, Teru Hideshima, Kenneth C. Anderson

Knight Cancer Institute

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

In the original version of this article (1), Fig. 4E was missing splice lines at p50 and p52, between TNFa and PBS-1086, and consequently the Nucleolin panel did not line up with the other two blots. These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors. Reference 1. Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, et al. Dual inhibition of canonical and noncanonical NF-kB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res 2012;18:4669–81.

Original language	English (US)
Pages (from-to)	2938
Number of pages	1
Journal	Clinical Cancer Research
Volume	25
Issue number	9
DOIs	https://doi.org/10.1158/1078-0432.CCR-19-0959
State	Published - 2019

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-19-0959

Fingerprint

Dive into the research topics of 'Erratum: Dual inhibition of canonical and noncanonical NF-kB pathways demonstrates significant antitumor activities in multiple myeloma (Clin Cancer Res (2019) 18(4669–81)Doi:10.1158/1078-0432.CCR-12-0779)'. Together they form a unique fingerprint.

Cite this

Fabre, C., Mimura, N., Bobb, K., Kong, S. Y., Gorgun, G. U., Cirstea, D., Hu, Y., Minami, J., Ohguchi, H., Zhang, J., Meshulam, J., Carrasco, R. D., Tai, Y. T., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2019). Erratum: Dual inhibition of canonical and noncanonical NF-kB pathways demonstrates significant antitumor activities in multiple myeloma (Clin Cancer Res (2019) 18(4669–81)Doi:10.1158/1078-0432.CCR-12-0779). Clinical Cancer Research, 25(9), 2938. https://doi.org/10.1158/1078-0432.CCR-19-0959

Erratum : Dual inhibition of canonical and noncanonical NF-kB pathways demonstrates significant antitumor activities in multiple myeloma (Clin Cancer Res (2019) 18(4669–81)Doi:10.1158/1078-0432.CCR-12-0779). / Fabre, Claire; Mimura, Naoya; Bobb, Kathryn et al.

In: Clinical Cancer Research, Vol. 25, No. 9, 2019, p. 2938.

Research output: Contribution to journal › Comment/debate › peer-review

Fabre, C, Mimura, N, Bobb, K, Kong, SY, Gorgun, GU, Cirstea, D, Hu, Y, Minami, J, Ohguchi, H, Zhang, J, Meshulam, J, Carrasco, RD, Tai, YT, Richardson, PG, Hideshima, T & Anderson, KC 2019, 'Erratum: Dual inhibition of canonical and noncanonical NF-kB pathways demonstrates significant antitumor activities in multiple myeloma (Clin Cancer Res (2019) 18(4669–81)Doi:10.1158/1078-0432.CCR-12-0779)', Clinical Cancer Research, vol. 25, no. 9, pp. 2938. https://doi.org/10.1158/1078-0432.CCR-19-0959

@article{f0deeaa77e8140c78cd2d608bbe357bb,

title = "Erratum: Dual inhibition of canonical and noncanonical NF-kB pathways demonstrates significant antitumor activities in multiple myeloma (Clin Cancer Res (2019) 18(4669–81)Doi:10.1158/1078-0432.CCR-12-0779)",

abstract = "In the original version of this article (1), Fig. 4E was missing splice lines at p50 and p52, between TNFa and PBS-1086, and consequently the Nucleolin panel did not line up with the other two blots. These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors. Reference 1. Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, et al. Dual inhibition of canonical and noncanonical NF-kB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res 2012;18:4669–81.",

author = "Claire Fabre and Naoya Mimura and Kathryn Bobb and Kong, {Sun Young} and Gorgun, {Gull u.} and Diana Cirstea and Yiguo Hu and Jiro Minami and Hiroto Ohguchi and Jie Zhang and Jeffrey Meshulam and Carrasco, {Ruben D.} and Tai, {Yu Tzu} and Richardson, {Paul G.} and Teru Hideshima and Anderson, {Kenneth C.}",

note = "Publisher Copyright: {\textcopyright} 2019 American Association for Cancer Research.",

year = "2019",

doi = "10.1158/1078-0432.CCR-19-0959",

language = "English (US)",

volume = "25",

pages = "2938",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "9",

}

TY - JOUR

T1 - Erratum

T2 - Dual inhibition of canonical and noncanonical NF-kB pathways demonstrates significant antitumor activities in multiple myeloma (Clin Cancer Res (2019) 18(4669–81)Doi:10.1158/1078-0432.CCR-12-0779)

AU - Fabre, Claire

AU - Mimura, Naoya

AU - Bobb, Kathryn

AU - Kong, Sun Young

AU - Gorgun, Gull u.

AU - Cirstea, Diana

AU - Hu, Yiguo

AU - Minami, Jiro

AU - Ohguchi, Hiroto

AU - Zhang, Jie

AU - Meshulam, Jeffrey

AU - Carrasco, Ruben D.

AU - Tai, Yu Tzu

AU - Richardson, Paul G.

AU - Hideshima, Teru

AU - Anderson, Kenneth C.

PY - 2019

Y1 - 2019

N2 - In the original version of this article (1), Fig. 4E was missing splice lines at p50 and p52, between TNFa and PBS-1086, and consequently the Nucleolin panel did not line up with the other two blots. These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors. Reference 1. Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, et al. Dual inhibition of canonical and noncanonical NF-kB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res 2012;18:4669–81.

AB - In the original version of this article (1), Fig. 4E was missing splice lines at p50 and p52, between TNFa and PBS-1086, and consequently the Nucleolin panel did not line up with the other two blots. These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors. Reference 1. Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, et al. Dual inhibition of canonical and noncanonical NF-kB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res 2012;18:4669–81.

UR - http://www.scopus.com/inward/record.url?scp=85065553128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065553128&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-19-0959

DO - 10.1158/1078-0432.CCR-19-0959

M3 - Comment/debate

C2 - 31043386

AN - SCOPUS:85065553128

VL - 25

SP - 2938

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -

Erratum: Dual inhibition of canonical and noncanonical NF-kB pathways demonstrates significant antitumor activities in multiple myeloma (Clin Cancer Res (2019) 18(4669–81)Doi:10.1158/1078-0432.CCR-12-0779)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this